BeOne Medicines (NASDAQ:ONC) CEO Sells $19,659,569.80 in Stock

Key Points

• CEO John Oyler sold 54,892 BeOne Medicines shares for approximately $19.66 million at an average price of $358.15, reducing his ownership by 18.57% to 240,743 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
• Oyler has made several additional stock sales in recent months, including transactions totaling more than $100 million in August and July.
• BeOne Medicines recently exceeded earnings expectations, reporting quarterly EPS of $2.05 versus the $1.40 consensus and revenue of $1.71 billion. Analysts maintain a consensus “Buy” rating with an average price target of $402.14.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 54,892 shares of the business's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $358.15, for a total value of $19,659,569.80. Following the completion of the sale, the chief executive officer owned 240,743 shares of the company's stock, valued at $86,222,105.45. This trade represents a 18.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Tuesday, August 11th, John Oyler sold 70,907 shares of BeOne Medicines stock. The shares were sold at an average price of $361.90, for a total value of $25,661,243.30.
• On Monday, August 10th, John Oyler sold 115,011 shares of BeOne Medicines stock. The stock was sold at an average price of $357.87, for a total transaction of $41,158,986.57.
• On Monday, July 20th, John Oyler sold 48,316 shares of BeOne Medicines stock. The stock was sold at an average price of $312.25, for a total value of $15,086,671.00.
• On Tuesday, July 21st, John Oyler sold 61,397 shares of BeOne Medicines stock. The shares were sold at an average price of $317.67, for a total transaction of $19,503,984.99.
• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The stock was sold at an average price of $298.34, for a total value of $3,489,981.32.
• On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The shares were sold at an average price of $304.35, for a total value of $14,767,062.00.
• On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The shares were sold at an average price of $305.95, for a total value of $44,626,172.95.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The stock was sold at an average price of $273.78, for a total value of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The stock was sold at an average price of $265.55, for a total value of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total value of $501,360.76.

BeOne Medicines Trading Down 0.1%

Shares of ONC stock traded down $0.22 on Wednesday, hitting $359.05. 314,911 shares of the stock traded hands, compared to its average volume of 289,218. The firm's 50-day moving average price is $299.80 and its two-hundred day moving average price is $308.98. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.06 and a current ratio of 3.40. The stock has a market capitalization of $39.39 billion, a PE ratio of 63.21 and a beta of 0.49. BeOne Medicines Ltd. - Sponsored ADR has a twelve month low of $253.95 and a twelve month high of $385.22.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.65. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. The firm had revenue of $1.71 billion during the quarter, compared to analyst estimates of $1.66 billion. As a group, analysts anticipate that BeOne Medicines Ltd. - Sponsored ADR will post 7.3 EPS for the current year.

Hedge Funds Weigh In On BeOne Medicines

A number of hedge funds have recently made changes to their positions in ONC. EFG International AG acquired a new stake in BeOne Medicines in the 4th quarter valued at approximately $25,000. Leonteq Securities AG acquired a new position in BeOne Medicines during the fourth quarter worth $35,000. Daiwa Securities Group Inc. purchased a new position in shares of BeOne Medicines during the second quarter worth $35,000. CWM LLC boosted its position in shares of BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company's stock worth $48,000 after buying an additional 39 shares during the period. Finally, Group One Trading LLC acquired a new stake in shares of BeOne Medicines in the fourth quarter valued at $61,000. Hedge funds and other institutional investors own 48.55% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Royal Bank Of Canada cut their price target on shares of BeOne Medicines from $451.00 to $450.00 and set an "outperform" rating for the company in a report on Thursday, August 6th. Guggenheim increased their price objective on BeOne Medicines from $420.00 to $430.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Truist Financial raised their target price on BeOne Medicines from $416.00 to $418.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Wells Fargo & Company assumed coverage on BeOne Medicines in a research report on Monday, May 4th. They issued an "overweight" rating and a $400.00 target price on the stock. Finally, Citizens Jmp upped their price target on BeOne Medicines from $396.00 to $405.00 and gave the company a "market outperform" rating in a research note on Thursday, August 6th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, BeOne Medicines presently has a consensus rating of "Buy" and an average price target of $402.14.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source